Samsung Biologics Capabilities Update July 2026: Large Molecule

If you're evaluating CDMOs for large molecule programs, Samsung Biologics has built a case worth examining closely. Jeff Mason, VP of Sales, walks through the company's full-service model, which now spans research, drug substance (DS) and drug product (DP) manufacturing, mRNA, antibody-drug conjugates (ADCs), and early-stage organoid services.

The numbers are hard to ignore. As of June 2026, Samsung Biologics supports more than 145 global clients, holds over 460 regulatory approvals across multiple agencies, and has completed 55-plus successful on-site inspections at their Songdo, South Korea campus. Their 99% batch success rate is the kind of figure that gets attention in manufacturing conversations. Total DS capacity now sits at approximately 845,000 liters, a figure that includes their recently acquired U.S. site in Rockville, Maryland.

The core argument here is multi-plant sourcing through what the company calls their "Excellence" framework, designed to give clients supply chain resilience without sacrificing quality or continuity. For organizations thinking through geographic diversification or scale-up risk, this is worth your time. Watch the full presentation to assess how their capacity and site network map to your pipeline needs.